IQVIA (NYSE:IQV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of IQVIA (NYSE:IQV) from a hold rating to a buy rating in a report released on Saturday morning.

Other analysts have also issued reports about the stock. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and upped their price target for the stock from $195.00 to $235.00 in a research note on Thursday, October 9th. Cowen downgraded IQVIA from a “buy” rating to a “hold” rating in a research report on Monday, November 3rd. Redburn Partners set a $214.00 price target on IQVIA in a research report on Wednesday, September 3rd. Evercore ISI boosted their price objective on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. Finally, Morgan Stanley raised their target price on IQVIA from $250.00 to $265.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $243.19.

IQVIA Stock Up 1.7%

Shares of IQVIA stock opened at $224.44 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA has a 1-year low of $134.65 and a 1-year high of $234.29. The business’s fifty day moving average price is $219.47 and its two-hundred day moving average price is $193.38. The company has a market capitalization of $38.22 billion, a P/E ratio of 30.79, a PEG ratio of 2.47 and a beta of 1.37.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts forecast that IQVIA will post 10.84 EPS for the current year.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider directly owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Large investors have recently made changes to their positions in the company. Physician Wealth Advisors Inc. boosted its stake in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. lifted its holdings in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in shares of IQVIA in the third quarter worth $30,000. Atlantic Union Bankshares Corp purchased a new position in shares of IQVIA during the third quarter valued at $36,000. Finally, Asset Dedication LLC raised its position in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after buying an additional 168 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.